Vascular dysfunction in idiopathic dilated cardiomyopathy

Nature Reviews Cardiology

Volumn 6, Issue 9, 2009, Pages 590-598

  Roura, Santiago ^a   Bayes Genis, Antoni ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; ANIMAL; AUTOIMMUNITY; CONGESTIVE CARDIOMYOPATHY; CORONARY BLOOD VESSEL; DISEASE MODEL; GENETIC PREDISPOSITION; HEART MUSCLE CELL; HUMAN; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; AUTOIMMUNITY; CARDIOMYOPATHY, DILATED; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; RISK FACTORS;

EID: 70350708776     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.130     Document Type: Review

References (100)

1. Richardson, P. et al. Report of the 1995 World Health Organization/international society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 93, 841-842 (1996).
2. Maron, B. J. et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113, 1807-1816 (2006).
3. Michels, V V et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N. Engl. J. Med. 326, 77-82 (1992).
4. Olson, T. M., Michels, V. V., Thibodeau, S. N., Tai, Y-S. and Keating, M. T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280, 750-752 (1998).
5. Ikeda, Y. and Ross, J. Models of dilated cardiomyopathy in the mouse and the hamster. Curr. Opin. Cardiol. 15, 197-201 (2000).
6. Recchia, F. A. and Lionetti, V. Animal models of dilated cardiomyopathy for translational research. Vet. Res. Commun. 31, 35-41 (2007).
7. Towbin, J. A. et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296, 1867-1876 (2006).
8. Towbin, J. A. and Bowles, N. E. The failing heart. Nature 415, 227-233 (2002).
9. Ai, X. and Pogwizd, S. M. Connexin 43 downregulation and dephosphorylation in nonischemic heart failure is associated with enhanced colocalized protein phosphatase type 2A. Circ. Res. 1, 54-63 (2005).
10. Seidman, J. G. and Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104, 557-567 (2001).
11. Osterziel, K. J. and Perrot, A. Dilated cardiomyopathy: more genes means more phenotypes. Eur. Heart J. 26, 751-754 (2005).
12. Perrot, A., Dietz, R. and Osterziel, K. J. Is there a common genetic basis for all familial cardiomyopathies. Eur. J. Heart Fail. 9, 4-6 (2007).
13. Parks, S. B. et al. Lamin A.C. Mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy. Am. Heart J. 156, 161-169 (2008).
14. Taylor, M. R. et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. J. Am. Coll. Cardiol. 41, 771-780 (2003).
15. Li, D. et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100, 461-464 (1999).
16. Knöll, R. et al. Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 116, 515-525 (2007).
17. Baboonian, C., Davies, M. J., Booth, J. C. and McKenna, W. J., Coxsackie B., Viruses and human heart disease. Curr. Top. Microbiol. Immunol. 223, 31-52 (1997).
18. Wessely, R. et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J. Clin. Invest. 102, 1444-1453 (1998).
19. Spotnitz, M. D. and Lesch, M., Idiopathic dilated cardiomyopathy as a late complication of healed viral (Coxsackie B virus) myocarditis: historical analysis, review of the literature, and a postulated unifying hypothesis. Prog. Cardiovasc. Dis. 49, 42-57 (2006).
20. Lappé, J. M., Pelfrey, C. M. and Tang, W. H. Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J. Card. Fail. 14, 521-530 (2008).
21. Jahns, R., Boivin, V., Schwarzbach, V., Ertl, G. and Lohse, M. J. Pathological autoantibodies in cardiomyopathy. Autoimmunity 41, 454-461 (2008).
22. Brutsaert, D. L. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol. Rev. 83, 59-115 (2003).
23. Liu, P. P., Mak, S. and Stewart, J. D. Potential role of the microvasculature in progression of heart failure. Am. J. Cardiol. 84, 23-26 (1999).
24. Brutsaert, D. L., Meulemans, A. L., Sipido, K. R. and Sys, S. U. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ. Res. 62, 358-366 (1988).
25. Ungureanu-Longrois, D. et al. Contractile responsiveness of ventricular myocytes to isoproterenol is regulated by induction of nitric oxide synthase activity in cardiac microvascular endothelial cells in heterotypic primary culture. Circ. Res. 77, 486-493 (1995).
26. Qi, X. L., Nguyen, T. L., Andries, L., Sys, S. U. and Rouleau, J. L. Vascular endothelial dysfunction contributes to myocardial depression in ischemia-reperfusion in the rat. Can. J. Physiol. Pharmacol. 78, 35-45 (1998).
27. Bell, J. P., Mosfer, S. I., Lang, D., Donaldson, F. and Lewis, M. J. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am. J. Physiol. Heart Circ. Physiol. 281, 1704-1710 (2001).
28. Qi, X. L. et al. Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation 100, 1338-1345 (1999).
29. Weiss, M. B. et al. Myocardial blood flow in congestive and hypertrophic cardiomyopathy: relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation 54, 484-494 (1976).
30. Parodi, O. et al. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation 88, 509-522 (1993).
31. Neglia, D. et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 105, 186-193 (2002).
32. Stolen, K. Q. et al. Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy. Am. J. Cardiol. 93, 64-68 (2004).
33. Harrison, C. V and Wood, P Hypertensive and ischemic heart disease; a comparative clinical and pathological study. Br. Heart J. 11, 205-229 (1949).
34. Mela, T et al. Coronary arterial dimension-to-left ventricular mass ratio in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 83, 1277-1280 (1999).
35. Mosseri, M. et al. The diameter of the epicardial coronary arteries in patients with dilated cardiomyopathy. Int. J. Cardiol. 62, 133-141 (1997).
36. Dodge, J. T., Brown, B. G., Bolson, E. L. and Dodge, H. T Lumen diameter of normal human coronary arteries. influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation 86, 232-246 (1992).
37. MacAlpin, R. N., Abbasi, A. S., Grollman, J. H. and Eber, L. Human coronary artery size during life: a cinearterioographic study. Radiology 108, 567-576 (1973).
38. Roura, S. et al. Idiopathic dilated cardiomyopathy exhibits defective vascularization and vessel formation. Eur. J. Heart Fail. 10, 995-1002 (2007).
39. Abraham, D. et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ. Res. 87, 644-647 (2000).
40. Schafer, R. et al. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy. Circulation 108, 1585-1591 (2003).
41. Tham, E., Wang, J., Piehl, F. and Weber, G. Upregulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by motochondrial dysfunction. Histochem. Cytochem. 50, 935-944 (2002).
42. Asahara, T et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
43. Gehling, U. M. et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106-3112 (2000).
44. Urbich, C. and Dimmeler, S. Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14, 318-322 (2004).
45. Rafii, S. and Lyden, D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9, 702-712 (2003).
46. Risau, W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
47. Asahara, T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228 (1999).
48. Crosby, J. R. et al. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 87, 728-730 (2000).
49. Murohara, T. et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J. Clin. Invest. 105, 1527-1536 (2000).
50. Shintani, S. et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103, 2776-2779 (2001).
51. Lev, E. I. et al. Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J. Vasc. Res. 42, 408-414 (2005).
52. Hill, J. M. et al. Circulating EPCs, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593-600 (2003).
53. Schmidt-Lucke, C. et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111, 2981-2987 (2005).
54. Urbich, C. and Dimmeler, S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 67, 1672-1676 (2005).
55. Quyyumi, A. A. and Hill, J. M. Circulating endothelial progenitor cells as novel biological determinants of vascular function and risk. Can. J. Cardiol. 20, 44-48 (2004).
56. Theiss, H. D. et al. Circulation of CD progenitor cell populations in patients with idiopathic dilated and ischaemic cardiomyopathy (DCM and iCM). Eur. Heart J. 28, 1258-1264.
57. Valgimigli, M. et al. CD and EPCs in patients with various degrees of congestive heart failure. Circulation 110, 1209-1212 (2004).
58. Zhou, Y L. et al. Decreased small arterial compliance with increased serum vascular endothelial growth factor-A and circulating endothelial progenitor cell in dilated cardiomyopathy. Chin. Med. J. 121, 316-320.
59. Masckauchan, T N., Shawber, C. J., Funahashi, Y, Li, C. M. and Kitajewski, J. Wnt/ß-catenin signaling induces proliferation, survival and interleukin-8 in human endothelial cells. Angiogenesis 8, 43-51 (2005).
60. Masckauchan, T. N. et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol. Biol. Cell 17, 5163-5172 (2006).
61. Wright, M., Aikawa, M., Szeto, W. and Papkoff, J. identification of a Wnt-responsive signal transduction pathway in primary endothelial cells. Biochem. Biophys. Res. Commun. 263, 384-388 (1999).
62. Blankesteijn, W. M., van Gijn, M. E., Essers-Janssen, Y. P., Daemen, M. J. and Smits, J. F., ß-Catenin, an inducer of uncontrolled cell proliferation and migration in malignancies, is localized in the cytoplasm of vascular endothelium during neovascularization after myocardial infarction. Am. J. Pathol. 157, 877-883 (2000).
63. Kim, K. I. et al. ß-Catenin overexpression augments angiogenesis and skeletal muscle regeneration through dual mechanism of vascular endothelial growth factor-mediated endothelial cell proliferation and progenitor cell mobilization. Arterioscler. Thromb. Vasc. Biol. 26, 91-98 (2006).
64. Hou, X. W. et al. Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc. Drugs Ther. 20, 85-91 (2006).
65. Mohamed, H. E., Asker, M. E., Ali, S. I. and El-Fattah, T M., Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4. J. Pharm. Pharmacol. 56, 757-768 (2004).
66. Herskowitz, A., Wolfgram, L. J., Rose, N. R. and Beisel, K. W. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains. J. Am. Coll. Cardiol. 9, 1311-1319 (1987).
67. Matsumori, A., Kawai, C., Crumpacker, C. S. and Abelmann, W. H. Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus. Jpn. Circ. J. 51, 661-664 (1987).
68. Neu, N. et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J. Immunol. 139, 3630-3636 (1987).
69. Kubota, T. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-a. Circ. Res. 81, 627-635 (1997).
70. Bryant, D. et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-a. Circulation 97, 1375-1381 (1998).
71. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
72. Taylor, J. A. et al. A spontaneous model for autoimmune myocarditis using the human MHC molecule HLA-DQ8. J. Immunol. 172, 2651-2658 (2004).
73. Coral-Vazquez, R. et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98, 465-474 (1999).
74. Wang, X. et al. Mouse model of desmin-related cardiomyopathy. Circulation 103, 2402-2407 (2001).
75. White, D. E. et al. Targeted ablation of iLK from the murine heart results in dilated cardiomyopathy and spontaneous heart failure. Genes Dev. 20, 2355-2360 (2006).
76. Bendig, G. et al. Integrin-linked kinase, a novel component of the cardiac mechanical stretch sensor, controls contractility in the zebrafish heart. Genes Dev. 20, 2361-2372 (2006).
77. Wang, J. et al. Cardiomyopathy associated with microcirculation dysfunction in laminin a4 chain-deficient mice. J. Biol. Chem. 281, 213-220 (2006).
78. Sakamoto, A. et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, 5-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc. Natl Acad. Sci. USA 94, 13873-13878 (1997).
79. Shannon, R. P. et al. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. 260, 1903-1911 (1991).
80. Allworth, M. S. et al. Effect of enalapril in dogs with pacing-induced heart failure. Am. J. Vet. Res. 56, 85-94 (1995).
81. Heinke, M. Y., Yao, M., Chang, D., Einstein, R. and dos Remedios, C. G., Apoptosis of ventricular and atrial myocytes from pacing-induced canine heart failure. Cardiovasc. Res. 49, 127-134 (2001).
82. Nikolaidis, L. A. et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955-961 (2004).
83. Nagareddy, F. R., McNeill, J. H. and MacLeod, K. M. Chronic inhibition of inducible nitric oxide synthase ameliorates cardiovascular abnormalities in streptozotocin diabetic rats. Eur. J. Pharmacol. 611, 53-59 (2009).
84. Podlowski, S. et al. ß1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy. J. Mol. Med. 78, 87-93 (2000).
85. Gilbert, E. M. et al. Long-term ß-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a doubleblind, randomized study of bucindolol versus placebo. Am. J. Med. 88, 223-239 (1990).
86. Urbich, C. and Dimmeler, S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int. 67, 1672-1676 (2005).
87. Assmus, B. et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res. 92, 1049-1055 (2003).
88. Walter, D. H. et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105, 3017-3024 (2002).
89. Llevadot, J. et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108, 399-405 (2001).
90. Dimmeler, S. et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the Pi 3-kinase/Akt pathway. J. Clin. Invest. 108, 391-397 (2001).
91. Node, K., Fujita, M., Kitakaze, M., Hori, M. and Liao, J. K, Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108, 839-843 (2003).
92. van der Harst, P, Voors, A. A. and van Veldhuisen, D. J. Short-term statin therapy and cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 109, 34 (2004).
93. Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HiF-1 induction of SDF-1. Nat. Med. 10, 858-864 (2004).
94. De Falco, E. et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104, 3472-3482 (2004).
95. iwaguro, H. et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105, 732-738 (2002).
96. Yi, C. et al. Transplantation of endothelial progenitor cells transferred by vascular endothelial growth factor gene for vascular regeneration of ischemic flaps. J. Surg. Res. 135, 100-106 (2006).
97. Cho, H. J. et al. Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrin-linked kinase. Arterioscler. Thromb. Vasc. Biol. 25, 1154-1160 (2005).
98. Pittenger, M. F. and Martin, B. J. Mesenchymal stem cells and their potential as cardiac therapeutics Circ. Res. 95, 9-20 (2004).
99. Nagaya, N. et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 112, 1128-1135 (2005).
100. ichim, T. E. et al. Placental mesenchymal and cord blood stem cell therapy for dilated cardiomyopathy. Reprod. Biomed. Online 16, 898-905 (2008).